Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

Switching patients in the age of long-acting recombinant products?

Escobar M, Santagostino E, Mancuso ME, Coppens M, Balasa V, Taylor JA, Iorio A, Negrier C.

Expert Rev Hematol. 2019;12(sup1):1-13. doi: 10.1080/17474086.2018.1564032.

PMID:
31282771
2.

Direct comparison of two extended-half-life recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A.

Shah A, Solms A, Wiegmann S, Ahsman M, Berntorp E, Tiede A, Iorio A, Mancuso ME, Zhivkov T, Lissitchkov T.

Ann Hematol. 2019 Sep;98(9):2035-2044. doi: 10.1007/s00277-019-03747-2. Epub 2019 Jun 24.

PMID:
31236667
3.

Emicizumab for hemophilia A without inhibitors.

Cafuir L, Kruse-Jarres R, Mancuso ME, Kempton CL.

Expert Rev Hematol. 2019 Jul;12(7):515-524. doi: 10.1080/17474086.2019.1624519. Epub 2019 Jun 4.

PMID:
31130012
4.

Evaluation of an automated chromogenic assay for Factor VIII clotting activity measurement in patients affected by haemophilia A.

Novembrino C, Boscolo Anzoletti M, Mancuso ME, Shinohara S, Peyvandi F.

Haemophilia. 2019 May;25(3):521-526. doi: 10.1111/hae.13746. Epub 2019 May 2.

PMID:
31044485
5.

Health-related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non-interventional study (NIS).

Mahlangu J, Oldenburg J, Callaghan MU, Shima M, Mancuso ME, Trask P, Recht M, Garcia C, Yang R, Lehle M, Macharia H, Asikanius E, Levy GG, Kruse-Jarres R, von Mackensen S.

Haemophilia. 2019 May;25(3):382-391. doi: 10.1111/hae.13731. Epub 2019 Apr 24.

PMID:
31016855
6.

Rescue factor VIII replacement to secure hemostasis in a patient with hemophilia A and inhibitors on emicizumab prophylaxis undergoing hip replacement.

Santagostino E, Mancuso ME, Novembrino C, Solimeno LP, Tripodi A, Peyvandi F.

Haematologica. 2019 Aug;104(8):e380-e382. doi: 10.3324/haematol.2018.215129. Epub 2019 Mar 28. No abstract available.

7.

Factor VIII: Long-established role in haemophilia A and emerging evidence beyond haemostasis.

Samuelson Bannow B, Recht M, Négrier C, Hermans C, Berntorp E, Eichler H, Mancuso ME, Klamroth R, O'Hara J, Santagostino E, Matsushita T, Kessler C.

Blood Rev. 2019 May;35:43-50. doi: 10.1016/j.blre.2019.03.002. Epub 2019 Mar 3. Review.

8.

Usefulness of bone microarchitectural and geometric DXA-derived parameters in haemophilic patients.

Ulivieri FM, Rebagliati GAA, Piodi LP, Solimeno LP, Pasta G, Boccalandro E, Fasulo MR, Mancuso ME, Santagostino E.

Haemophilia. 2018 Nov;24(6):980-987. doi: 10.1111/hae.13611. Epub 2018 Oct 1.

PMID:
30273987
9.

GlycoPEGylated recombinant factor IX for hemophilia B in context.

Santagostino E, Mancuso ME.

Drug Des Devel Ther. 2018 Sep 11;12:2933-2943. doi: 10.2147/DDDT.S121743. eCollection 2018. Review.

10.

Once-weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9-GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm™ trials.

Oldenburg J, Carcao M, Lentz SR, Mahlangu J, Mancuso ME, Matsushita T, Négrier C, Clausen WHO, Ehrenforth S, Young G.

Haemophilia. 2018 Nov;24(6):911-920. doi: 10.1111/hae.13608. Epub 2018 Sep 24.

PMID:
30248217
11.

The predictive value of factor VIII/factor IX levels to define the severity of hemophilia: communication from the SSC of ISTH.

Mancuso ME, Bidlingmaier C, Mahlangu JN, Carcao M, Tosetto A; subcommittee on factor viii, factor ix and rare coagulation disorders.

J Thromb Haemost. 2018 Oct;16(10):2106-2110. doi: 10.1111/jth.14257. Epub 2018 Sep 5. No abstract available.

PMID:
30182468
12.

Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.

Mahlangu J, Oldenburg J, Paz-Priel I, Negrier C, Niggli M, Mancuso ME, Schmitt C, Jiménez-Yuste V, Kempton C, Dhalluin C, Callaghan MU, Bujan W, Shima M, Adamkewicz JI, Asikanius E, Levy GG, Kruse-Jarres R.

N Engl J Med. 2018 Aug 30;379(9):811-822. doi: 10.1056/NEJMoa1803550.

13.

Common themes and challenges in hemophilia care: a multinational perspective.

Stoffman J, Andersson NG, Branchford B, Batt K, D'Oiron R, Escuriola Ettingshausen C, Hart DP, Jiménez Yuste V, Kavakli K, Mancuso ME, Nogami K, Ramírez C, Wu R.

Hematology. 2019 Dec;24(1):39-48. doi: 10.1080/10245332.2018.1505225. Epub 2018 Aug 3.

PMID:
30073913
14.

Distal radius microstructure and finite element bone strain are related to site-specific mechanical loading and areal bone mineral density in premenopausal women.

Mancuso ME, Johnson JE, Ahmed SS, Butler TA, Troy KL.

Bone Rep. 2018 Apr 14;8:187-194. doi: 10.1016/j.bonr.2018.04.001. eCollection 2018 Jun.

15.

Exercise Early and Often: Effects of Physical Activity and Exercise on Women's Bone Health.

Troy KL, Mancuso ME, Butler TA, Johnson JE.

Int J Environ Res Public Health. 2018 Apr 28;15(5). pii: E878. doi: 10.3390/ijerph15050878. Review.

16.

Muscle function deterioration in patients with haemophilia: Prospective experience from Costa Rica.

Seuser A, Navarrete-Duran M, Auerswald G, Mancuso ME.

Haemophilia. 2018 Jul;24(4):e230-e241. doi: 10.1111/hae.13455. Epub 2018 Mar 26.

PMID:
29578254
17.

Risk Factors for the Progression from Low to High Titres in 260 Children with Severe Haemophilia A and Newly Developed Inhibitors.

Mancuso ME, Fischer K, Santagostino E, Oldenburg J, Platokouki H, Königs C, Escuriola-Ettingshausen C, Rivard GE, Cid AR, Carcao M, Ljung R, Petrini P, Altisent C, Kenet G, Liesner R, Kurnik K, Auerswald G, Chambost H, Mäkipernaa A, Molinari AC, Williams M, van den Berg HM; European Pediatric Network for Haemophilia Management (PedNet) the REMAIN (REal life MAnagement of children with INhibitors) Study Group.

Thromb Haemost. 2017 Dec;117(12):2274-2282. doi: 10.1160/TH17-01-0059. Epub 2017 Dec 6.

PMID:
29212115
18.

Ageing successfully with haemophilia: A multidisciplinary programme.

Boccalandro E, Mancuso ME, Riva S, Pisaniello DM, Ronchetti F, Santagostino E, Peyvandi F, Solimeno LP, Mannucci PM, Pasta G.

Haemophilia. 2018 Jan;24(1):57-62. doi: 10.1111/hae.13308. Epub 2017 Aug 6.

PMID:
28780767
19.

Intracranial haemorrhage in children and adolescents with severe haemophilia A or B - the impact of prophylactic treatment.

Andersson NG, Auerswald G, Barnes C, Carcao M, Dunn AL, Fijnvandraat K, Hoffmann M, Kavakli K, Kenet G, Kobelt R, Kurnik K, Liesner R, Mäkipernaa A, Manco-Johnson MJ, Mancuso ME, Molinari AC, Nolan B, Perez Garrido R, Petrini P, Platokouki HE, Shapiro AD, Wu R, Ljung R.

Br J Haematol. 2017 Oct;179(2):298-307. doi: 10.1111/bjh.14844. Epub 2017 Jul 12.

PMID:
28699675
20.

Involvement of the IgE-basophil system and mild complement activation in haemophilia B with anti-factor IX neutralizing antibodies and anaphylaxis.

Cugno M, Mancuso ME, Tedeschi A, Santagostino E, Lorini M, Carbonelli V, Peyvandi F, Mannucci PM.

Haemophilia. 2017 Jul;23(4):e348-e353. doi: 10.1111/hae.13282. Epub 2017 Jun 8.

PMID:
28594432
21.

Polypharmacy in older adults with severe haemophilia.

Riva S, Mancuso ME, Cortesi L, Nobili A, Santagostino E, Peyvandi F, Mannucci PM.

Haemophilia. 2018 Jan;24(1):e1-e3. doi: 10.1111/hae.13262. Epub 2017 May 24. No abstract available.

PMID:
28544483
22.

Platelets: much more than bricks in a breached wall.

Mancuso ME, Santagostino E.

Br J Haematol. 2017 Jul;178(2):209-219. doi: 10.1111/bjh.14653. Epub 2017 Apr 17. Review.

PMID:
28419428
23.

Outcome of Clinical Trials with New Extended Half-Life FVIII/IX Concentrates.

Mancuso ME, Santagostino E.

J Clin Med. 2017 Mar 28;6(4). pii: E39. doi: 10.3390/jcm6040039. Review.

24.

The second Team Haemophilia Education Meeting, 2016, Frankfurt, Germany.

Berntorp E, Dargaud Y, Hart D, Lobet S, Mancuso ME, d'Oiron R, Perry D, Pollard D, van den Berg M, Blatný J, Chambost H, Doria AS, Holme PA, Kaczmarek R, Mantovani L, McLaughlin P, Nanayakkara L, Petrini P, Sannié T, Laane E, Maia R, Dettoraki A, Farrell A, Halimeh S, Raza S, Taylor S.

Eur J Haematol. 2017 Jan;98 Suppl 85:1-15. doi: 10.1111/ejh.12828.

PMID:
28101938
25.

Applying a deliberation model to the analysis of consultations in haemophilia: Implications for doctor-patient communication.

Lamiani G, Bigi S, Mancuso ME, Coppola A, Vegni E.

Patient Educ Couns. 2017 Apr;100(4):690-695. doi: 10.1016/j.pec.2016.11.021. Epub 2016 Nov 28.

PMID:
27914734
26.

Platelets from glioblastoma patients promote angiogenesis of tumor endothelial cells and exhibit increased VEGF content and release.

Di Vito C, Navone SE, Marfia G, Abdel Hadi L, Mancuso ME, Pecci A, Crisà FM, Berno V, Rampini P, Campanella R, Riboni L.

Platelets. 2017 Sep;28(6):585-594. doi: 10.1080/09537104.2016.1247208. Epub 2016 Nov 29.

PMID:
27897101
27.

Summary report of the First International Conference on inhibitors in haemophilia A.

Lacroix-Desmazes S, Scott DW, Goudemand J, Van Den Berg M, Makris M, Van Velzen AS, Santagostino E, Lillicrap D, Rosendaal FR, Hilger A, Sauna ZE, Oldenburg J, Mantovani L, Mancuso ME, Kessler C, Hay CRM, Knoebl P, Di Minno G, Hoots K, Bok A, Brooker M, Buoso E, Mannucci PM, Peyvandi F.

Blood Transfus. 2017 Oct;15(6):568-576. doi: 10.2450/2016.0252-16. Epub 2016 Nov 25. No abstract available.

28.

Evaluation of the utility of the ISTH-BAT in haemophilia carriers: a multinational study.

James PD, Mahlangu J, Bidlingmaier C, Mingot-Castellano ME, Chitlur M, Fogarty PF, Cuker A, Mancuso ME, Holme PA, Grabell J, Satkunam N, Hopman WM, Mathew P; Global Emerging HEmostasis Experts Panel (GEHEP).

Haemophilia. 2016 Nov;22(6):912-918. doi: 10.1111/hae.13089.

PMID:
27868369
29.

Long-acting recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in children. Results of a phase 3 trial.

Kenet G, Chambost H, Male C, Lambert T, Halimeh S, Chernova T, Mancuso ME, Curtin J, Voigt C, Li Y, Jacobs I, Santagostino E; PROLONG-9FP Investigator Study Group.

Thromb Haemost. 2016 Sep 27;116(4):659-68. doi: 10.1160/TH16-03-0179. Epub 2016 Sep 1.

30.

Low-factor consumption for major surgery in haemophilia B with long-acting recombinant glycoPEGylated factor IX.

Escobar MA, Tehranchi R, Karim FA, Caliskan U, Chowdary P, Colberg T, Giangrande P, Giermasz A, Mancuso ME, Serban M, Tsay W, Mahlangu JN.

Haemophilia. 2017 Jan;23(1):67-76. doi: 10.1111/hae.13041. Epub 2016 Aug 1.

PMID:
27480487
31.

The first Team Haemophilia Education meeting, 2015, Amsterdam, The Netherlands.

Berntorp E, Hart D, Mancuso ME, d'Oiron R, Perry D, O'Mahony B, Kaczmarek R, Crato M, Pasi J, Miners A, Carlsson KS, Kitchen S, Boehlen F, Giangrande P, Cebura E, Uitslager N, Osooli M, Janeckova D, Haldon R, Rivolta GF.

Eur J Haematol. 2016 Jul;97 Suppl 83:3-18. doi: 10.1111/ejh.12760. Erratum in: Eur J Haematol. 2016 Dec;97(6):594.

PMID:
27272000
32.

A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A.

Peyvandi F, Mannucci PM, Garagiola I, El-Beshlawy A, Elalfy M, Ramanan V, Eshghi P, Hanagavadi S, Varadarajan R, Karimi M, Manglani MV, Ross C, Young G, Seth T, Apte S, Nayak DM, Santagostino E, Mancuso ME, Sandoval Gonzalez AC, Mahlangu JN, Bonanad Boix S, Cerqueira M, Ewing NP, Male C, Owaidah T, Soto Arellano V, Kobrinsky NL, Majumdar S, Perez Garrido R, Sachdeva A, Simpson M, Thomas M, Zanon E, Antmen B, Kavakli K, Manco-Johnson MJ, Martinez M, Marzouka E, Mazzucconi MG, Neme D, Palomo Bravo A, Paredes Aguilera R, Prezotti A, Schmitt K, Wicklund BM, Zulfikar B, Rosendaal FR.

N Engl J Med. 2016 May 26;374(21):2054-64. doi: 10.1056/NEJMoa1516437.

33.

Low thrombin generation during major orthopaedic surgery fails to predict the bleeding risk in inhibitor patients treated with bypassing agents.

Mancuso ME, Chantarangkul V, Clerici M, Fasulo MR, Padovan L, Scalambrino E, Peyvandi F, Tripodi A, Santagostino E.

Haemophilia. 2016 Jul;22(4):e292-300. doi: 10.1111/hae.12939. Epub 2016 May 16.

PMID:
27197961
34.

The thrombin generation assay distinguishes inhibitor from non-inhibitor patients with severe haemophilia A.

Mancuso ME, Chantarangkul V, Clerici M, Fasulo MR, Padovan L, Scalambrino E, Peyvandi F, Tripodi A, Santagostino E.

Haemophilia. 2016 Jul;22(4):e286-91. doi: 10.1111/hae.12927. Epub 2016 May 11.

PMID:
27166132
35.

Tailoring hemostatic therapies to lower inhibitor development in previously untreated patients with severe hemophilia A.

Mannucci PM, Mancuso ME, Franchini M.

J Thromb Haemost. 2016 Jul;14(7):1330-6. doi: 10.1111/jth.13356. Epub 2016 Jun 22. Review. Erratum in: J Thromb Haemost. 2016 Nov;14 (11):2320.

36.

Innovative Pharmacological Therapies for the Hemophilias Not Based on Deficient Factor Replacement.

Mannucci PM, Mancuso ME, Santagostino E, Franchini M.

Semin Thromb Hemost. 2016 Jul;42(5):526-32. doi: 10.1055/s-0036-1571310. Epub 2016 May 5. Review.

PMID:
27148843
37.

A recurrent F8 mutation (c.6046C>T) causing hemophilia A in 8% of northern Italian patients: evidence for a founder effect.

Garagiola I, Seregni S, Mortarino M, Mancuso ME, Fasulo MR, Notarangelo LD, Peyvandi F.

Mol Genet Genomic Med. 2015 Dec 14;4(2):152-9. doi: 10.1002/mgg3.189. eCollection 2016 Mar.

38.

Whole-exome sequencing to identify genetic risk variants underlying inhibitor development in severe hemophilia A patients.

Gorski MM, Blighe K, Lotta LA, Pappalardo E, Garagiola I, Mancini I, Mancuso ME, Fasulo MR, Santagostino E, Peyvandi F.

Blood. 2016 Jun 9;127(23):2924-33. doi: 10.1182/blood-2015-12-685735. Epub 2016 Apr 8.

39.

Platelet-derived sphingosine-1-phosphate and inflammation: from basic mechanisms to clinical implications.

Vito CD, Hadi LA, Navone SE, Marfia G, Campanella R, Mancuso ME, Riboni L.

Platelets. 2016 Jul;27(5):393-401. doi: 10.3109/09537104.2016.1144179. Epub 2016 Mar 7. Review.

PMID:
26950429
40.

Increased VEGF levels in one case of papillary tumor of the pineal region with intracranial haemorrhage at presentation: a potential surrogate indicator of tumor angiogenesis and aggressiveness?

Marfia G, Ampollini A, Navone SE, DI Vito C, Bornati A, Miozzo M, DE Rezende G, Rampini P, Riboni L, Mancuso ME, Campanella R.

J Neurosurg Sci. 2016 Jan 8. [Epub ahead of print]

PMID:
26745494
41.

BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial.

Ljung R, Kenet G, Mancuso ME, Kaleva V, Rusen L, Tseneklidou-Stoeter D, Michaels LA, Shah A, Hong W, Maas Enriquez M; investigators of the LEOPOLD Kids Trial.

Haemophilia. 2016 May;22(3):354-60. doi: 10.1111/hae.12866. Epub 2015 Dec 9.

PMID:
26663410
42.

Thrombin Generation Assay as a Laboratory Monitoring Tool during Bypassing Therapy in Patients with Hemophilia and Inhibitors.

Mancuso ME, Fasulo MR.

Semin Thromb Hemost. 2016 Feb;42(1):30-5. doi: 10.1055/s-0035-1564842. Epub 2015 Nov 23. Review.

PMID:
26595153
43.

IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII.

Matino D, Gargaro M, Santagostino E, Di Minno MN, Castaman G, Morfini M, Rocino A, Mancuso ME, Di Minno G, Coppola A, Talesa VN, Volpi C, Vacca C, Orabona C, Iannitti R, Mazzucconi MG, Santoro C, Tosti A, Chiappalupi S, Sorci G, Tagariello G, Belvini D, Radossi P, Landolfi R, Fuchs D, Boon L, Pirro M, Marchesini E, Grohmann U, Puccetti P, Iorio A, Fallarino F.

J Clin Invest. 2015 Oct 1;125(10):3766-81. doi: 10.1172/JCI81859. Epub 2015 Aug 31.

44.

Cognitive and psychological profiles in treatment compliance: a study in an elderly population with hemophilia.

Riva S, Nobili A, Djade CD, Mancuso ME, Santagostino E, Pravettoni G.

Clin Interv Aging. 2015 Jul 9;10:1141-6. doi: 10.2147/CIA.S84749. eCollection 2015.

45.

Central venous access device (CVAD) complications in Haemophilia with inhibitors undergoing immune tolerance induction: Lessons from the international immune tolerance study.

Rodriguez V, Mancuso ME, Warad D, Hay CR, DiMichele DM, Valentino L, Kenet G, Kulkarni R.

Haemophilia. 2015 Sep;21(5):e369-74. doi: 10.1111/hae.12740. Epub 2015 Jul 14.

PMID:
26178581
46.

Inhibitors in nonsevere haemophilia A: outcome and eradication strategies.

van Velzen AS, Eckhardt CL, Hart DP, Peters M, Rangarajan S, Mancuso ME, Smiers FJ, Khair K, Petrini P, Jiménez-Yuste V, Hay CR, van der Bom JG, Yee TT, Fijnvandraat K; INSIGHT study group.

Thromb Haemost. 2015 Jul;114(1):46-55. doi: 10.1160/TH14-11-0940. Epub 2015 Apr 16.

PMID:
25879247
47.

Benefits of prophylaxis versus on-demand treatment in adolescents and adults with severe haemophilia A: the POTTER study.

Tagliaferri A, Feola G, Molinari AC, Santoro C, Rivolta GF, Cultrera DB, Gagliano F, Zanon E, Mancuso ME, Valdré L, Mameli L, Amoresano S, Mathew P, Coppola A; POTTER Study Group.

Thromb Haemost. 2015 Jul;114(1):35-45. doi: 10.1160/TH14-05-0407. Epub 2015 Apr 9.

PMID:
25855376
48.

Presentation and management of acute coronary syndromes among adult persons with haemophilia: results of an international, retrospective, 10-year survey.

Fogarty PF, Mancuso ME, Kasthuri R, Bidlingmaier C, Chitlur M, Gomez K, Holme PA, James P, Kruse-Jarres R, Mahlangu J, Mingot-Castellano ME, Soni A; Global Emerging Hemophilia Panel (GEHEP).

Haemophilia. 2015 Sep;21(5):589-97. doi: 10.1111/hae.12652. Epub 2015 Feb 17.

PMID:
25689278
49.

Factors influencing illness representations and perceived adherence in haemophilic patients: a pilot study.

Lamiani G, Strada I, Mancuso ME, Coppola A, Vegni E, Moja EA; Pro-Adherence Study Group.

Haemophilia. 2015 Sep;21(5):598-604. doi: 10.1111/hae.12654. Epub 2015 Feb 16.

PMID:
25684356
50.

Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A. A patient-level meta-analysis.

Marcucci M, Mancuso ME, Santagostino E, Kenet G, Elalfy M, Holzhauer S, Bidlingmaier C, Escuriola Ettingshausen C, Iorio A, Nowak-Göttl U.

Thromb Haemost. 2015 May;113(5):958-67. doi: 10.1160/TH14-07-0621. Epub 2015 Jan 29.

PMID:
25631402

Supplemental Content

Loading ...
Support Center